Ionis Pharmaceuticals: Blockbuster Potential as a Price Driver
Reading Time: 3 minutes
Ionis Pharmaceuticals is a leading developer of drugs based on antisense technology. This technology aims to stop the production of harmful proteins by blocking the genetic blueprint (mRNA). Ionis has a wide range of drugs in development, ranging from early-stage (preclinical) to late-stage (Phase 3). Ionis has announced positive topline results from the Phase 3 trials CORE and CORE2 with Olezarsen in patients with severe hypertriglyceridemia (sHTG). Ionis Pharmaceuticals (NASDAQ: IONS) is a leading biotechnology company. The company...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
